Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Omeros Corporation's stock surges as narsoplimab data shows 68% lower death risk in HSCT-TMA patients. Click to learn about the potential and risks of OMER stock.
Targeted Oncology14 小时
Study Highlights Risks of Tandem ASCT in High-Risk Neuroblastoma
A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but ...